Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.54 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.36 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015963 | 0.89 | P2RX7 (0.55) | P2RX7ANO1ALDH1A1 | |
| SCHEMBL2995172 | 0.84 | P2RX7 (0.44) | P2RX7ANO1TAS2R8 | |
| SCHEMBL308155 | 0.84 | P2RX7 (0.71) | P2RX7ANO1TAS2R8 | |
| SCHEMBL13243941 | 0.83 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL3016089 | 0.83 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL2995313 | 0.83 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL4141045 | 0.83 | P2RX7 (0.48) | P2RX7ANO1ALDH1A1POLBKDM4E | |
| SCHEMBL13243937 | 0.82 | P2RX7 (0.58) | P2RX7ALDH1A1 | |
| SCHEMBL13243931 | 0.82 | P2RX7 (0.58) | P2RX7ALDH1A1 | |
| SCHEMBL13243959 | 0.80 | P2RX7 (0.51) | P2RX7ALDH1A1POLBKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2007109201-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184802-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885ANO1 1352/4885TAS2R8 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.